Document Detail

The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
MedLine Citation:
PMID:  2495745     Owner:  NLM     Status:  MEDLINE    
To evaluate the thrombolytic effects of the native tissue-type plasminogen activator (t-PA), the authors used a thrombus model simulating clinical situations. The native t-PA (AK-124) was obtained from human-derived normal cells. Experimental canine coronary thrombosis was produced by partial constriction and endothelial denudation of the vessel. In 19 dogs, coronary occlusive thrombus was produced. Three hours after total occlusion of the coronary artery with thrombus, the authors attempted the thrombolytic therapy in 16 dogs. Histologically, three-hour thrombus was composed of a mixture of platelet aggregates, fibrin, and blood cells. They infused 0.375 mg/kg t-PA intravenously in 7 dogs and 20,000 IU/kg urokinase (UK) in 9. Coronary recanalization was achieved in 5 (71%) with t-PA infusion and 6 (67%) with UK infusion. Plasma fibrinogen levels decreased to 76% of preinfusion value in the dogs with t-PA infusion and to 34% in those with UK infusion. Coronary reocclusion occurred in 2 dogs with t-PA and 3 with UK. Thus, the native t-PA (AK-124) can provide coronary thrombolysis without severe depletion of plasma fibrinogen levels.
T Tomaru; Y Uchida; H Sonoki; M Tsukamoto; T Sugimoto
Related Documents :
2972815 - Demonstration of reperfusion after thrombolysis with technetium-99m isonitrile myocardi...
15651765 - Thrombolytic therapy for myocardial infarction facilitated by mobile coronary care.
24029205 - Thyroid storm presenting as congestive heart failure and protein-s deficiency-induced b...
25130115 - Severe hypokalemia and thyrotoxic paralysis from painless thyroiditis complicated by li...
19962465 - Usefulness of the duke sudden cardiac death risk score for predicting sudden cardiac de...
23918775 - Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adver...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Angiology     Volume:  40     ISSN:  0003-3197     ISO Abbreviation:  Angiology     Publication Date:  1989 May 
Date Detail:
Created Date:  1989-05-19     Completed Date:  1989-05-19     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0203706     Medline TA:  Angiology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  429-35     Citation Subset:  IM    
Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Disease / drug therapy*
Coronary Thrombosis / drug therapy*
Fibrin / drug effects
Fibrinogen / analysis
Platelet Aggregation / drug effects
Tissue Plasminogen Activator / therapeutic use*
Urokinase-Type Plasminogen Activator / therapeutic use
Reg. No./Substance:
9001-31-4/Fibrin; 9001-32-5/Fibrinogen; EC Plasminogen Activator; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Alfentanil requirement in Crohn's disease. Increased alfentanil dose requirement in patients with Cr...
Next Document:  An improved noninvasive method for measurement of cardiac output and evaluation of left-sided cardia...